Best Microdose GLP-1 Company in 2026

Noom Med is a clear starting point because it publishes a distinct Microdose GLP-1 program rather than leaving low-dose care as an informal option. Its pages describe clinician review, dose optimisation guidance, coaching support and a community of members on similar plans. That structure suits people who want behaviour change alongside medicine, rather than a prescription alone.

The published pricing notes an initial period from $79 plus tax, with $179 per month plus tax for a later subscription period, depending on program selection. Those figures can change, so confirm the current page before signing up. Noom also states plainly that compounded semaglutide is produced in an FDA-registered facility but has not been reviewed by the FDA for safety, efficacy or quality. That disclosure is important, and it should prompt a careful conversation with the clinician about branded versus compounded options.

Hims is one of the largest telehealth brands in the United States, and its scale is its main appeal. Patients get a familiar sign-up flow, clinician review and a platform that also covers other health needs, which can make ongoing care simpler to manage in one place. Published reports in 2026 describe Hims moving from compounded semaglutide toward branded products after a settlement and supply agreement, with plans historically near $199 per month on annual commitments.

That shift is also the catch. If you are specifically seeking a compounded low-dose plan, Hims may no longer match that need, and current availability should be confirmed directly. For people who prefer branded medicines and a large, established platform, the change may be reassuring rather than a drawback. Either way, read the current program terms carefully before deciding.

Ro offers a clinician-led weight-management program that includes medical review, ongoing messaging and support for GLP-1 treatment where clinically appropriate. Its structure appeals to people who want regular clinician contact rather than a one-time prescription. The platform also covers other health services, which can help when weight care connects with related conditions.

The main limits are cost and coverage. GLP-1 medicines are expensive, insurance rules vary, and the total monthly cost depends on whether treatment uses a branded or compounded product and on the plan length. Ro publishes program details on its site, but the exact price for an individual depends on clinical review and current offers. Ask what is included, such as clinician visits, messaging and lab work, before comparing headline prices.

Found pairs clinician-led medication care with coaching, tracking and community support. That combination suits people who want help with eating, activity and habits alongside any prescription. The program is built around a personal plan, with follow-up intended to adjust care as progress and side effects change.

As with other providers, the honest catch is price and fit. Found is a subscription program, and the total cost depends on the medication prescribed and the plan chosen. Coaching helps some people a great deal and matters less to others, so weigh whether you will use it. Confirm whether lab work, clinician visits and messaging are included, and whether compounded or branded medicines are offered in your state.

WeightWatchers Clinic builds on a weight program many people already know, adding clinician-led medication care for eligible members. The behaviour side, including food tracking, activity and group support, is more developed than at most telehealth-only rivals. That can matter for maintenance, where habits and support often decide whether results last.

The limit is eligibility and structure. Not every member will qualify for medication, and the clinic program may sit alongside a separate membership cost. Low-dose or maintenance discussions still need a clinician review, and the program should not be treated as a shortcut to a prescription. For people who already value the WeightWatchers approach, the clinic option keeps behaviour support and medical care closer together.

NexLife describes a flat-rate compounded GLP-1 program that includes microdose and sublingual protocols, a personalised nutrition plan, a coaching call and provider review with ongoing guidance. Its published material also describes independent third-party testing of batches for potency, sterility, pH and endotoxin levels before shipping, and pharmacy partners with state licensure and other credentials.

Those details are useful for comparison, but they do not remove the central caution about compounded medicines. Compounded products are not FDA approved, and individual results vary. NexLife is also less established than the largest telehealth brands, so check current reviews, state availability and cancellation terms. For people who want a program that states its low-dose approach openly, NexLife is worth shortlisting alongside larger providers.

Lttl is a newer direct-to-consumer telehealth brand that describes personalised GLP-1 weight management, longevity support and microdosed therapy. Its launch material states that licensed providers review history and goals, tailor plans to the individual, and that it partners with state-licensed compounding pharmacies using active ingredients from FDA-registered manufacturers with certificates of analysis.

That is a clear statement of intent, but a newer brand naturally has less public history to judge. Pricing, state availability and the exact medicines offered should be confirmed on its current site before any decision. As with all compounded options, the FDA review limit applies. Lttl fits best as a provider to compare on support, transparency and clinician access, not as a guaranteed low-dose solution.

PlushCare is a virtual primary care platform that also offers weight-management care. Its appeal is continuity: the same kind of clinician who manages other health needs can discuss weight, related conditions and medication options in one place. That broader view can help when weight treatment interacts with blood pressure, diabetes risk or other medicines.

The trade is specialisation. PlushCare does not present itself primarily as a microdose GLP-1 company, so its low-dose approach, if offered, will depend on the individual clinician and the clinical picture. It may suit people who already use virtual primary care and want weight care inside that relationship. People seeking a dedicated low-dose program with published protocols may prefer Noom Med or NexLife for comparison.